Clinical Trials
20 trialsNCT02037256 2021-05-10
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma
Barbara Ann Karmanos Cancer Institute
Phase NA Completed
NCT00980395 2019-12-30
VCR
University of Arizona
Phase 2 Completed
NCT00711828 2019-04-16
Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma
Mayo Clinic
Phase 2 Completed
NCT00295932 2018-11-20
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02877082 2018-04-30
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Emory University
Phase 2 Terminated
NCT00963274 2018-04-23
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Virginia Commonwealth University
Phase 1 Completed
NCT00772668 2017-12-11
Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL
University of Miami
Phase NA Terminated
NCT03335098 2017-11-07
BOMB-THROW
Seoul National University Hospital
Phase 2 Unknown
NCT00837174 2017-09-19
COMBOSTAT
The Methodist Hospital Research Institute
Phase 2 Withdrawn
NCT00671112 2015-10-28
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated
NCT00210392 2015-03-30
VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Terminated
NCT00373906 2013-11-27
Velcade in MALT Lymphoma Patients
Medical University of Vienna
Phase 2 Completed
NCT00006098 2013-06-18
PS-341 in Treating Patients With Hematologic Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00004002 2012-11-09
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
NYU Langone Health
Phase 1 Completed
NCT00093769 2012-10-04
Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00237627 2012-05-18
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Completed
NCT00006362 2011-08-03
PS-341 in Treating Patients With Advanced Cancer
Mayo Clinic
Phase 1 Completed
NCT00142129 2011-06-27
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00210327 2009-07-22
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Completed